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EVIDENCE BASED NEURO-ONCOLOGY
Tumour Treating Fields (TTFs) for recurrent and newly diagnosed glioblastoma
multiforme
Farhan A. Mirza, Muhammad Shahzad Shamim

Abstract
In the last decade, significant advances have been
made in Glioblastoma Multiforme treatment with the
novel use of alternating electrical fields, also termed
as tumour treating fields (TTFs). This modality has
shown promising results in recurrent and newly
diagnosed GBM patients, and according to some, may
soon be considered an addition to the previously
known 'trifecta' of GBM standard of care, i.e., surgery,
chemo and radiation therapy.Here we review the
existing data on TTF for both recurrent and newly
diagnosed GBM. This review does not discuss the
limitations of TTF, especially from compliance and
cost point of view.
Keywords: Glioblastoma, Tumour Treating Fields,
Alternating Electric Fields, Progression Free Survival,
Overall Survival

Introduction
In the first in vivo study involving Tumour Treating
Fields (TTF) was tested in ten patients with recurrent
GBMs using non-invasive transducer arrays attached to
the scalp, with significant improvement noted in time
to tumour progression (TTP) [26.1 vs 9.5 weeks],
progression free survival (PFS) at 6 months [50% vs
15.3%,], and overall survival (OS) [median 62.2 vs 29.3
weeks], without any systemic toxicity.1 In 2009, the
same group performed a second pilot trial to
understand the efficacy of TTFs in newly diagnosed
patients in combination with standard adjuvant TMZ,
and again noted very promising results (Median PFS
[155 vs 31 weeks] and improved median OS [> 39 vs
14.7 months]).2

Review of Evidence
We queried the PubMed database with the phrases
'tumour treating fields in glioblastoma' and
'alternating electric fields in brain tumours'.
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Figure: An example of TTF applied on a patient.13

Abstracts of articles describing this treatment
modality were reviewed. Articles addressing use of
tumour treating fields in high grade gliomas were
reviewed.

Role in Recurrent GBM
Median time to recurrence for GBMis approximately
seven months and median survival 15-18 months.
Repeat craniotomy and Bevacizumab have shown to
be beneficial in the recurrent setting.3 Despite this,
about 60% of patients relapse on Bevacizumab, can
have serious side effects, develop resistance to the
drug, and also fail to respond to any further
chemotherapy. 4
In 2012, Stupp et al published their results on the first
Phase III trial of 237 patients studying the effects of
TTFs alone, compared with standard chemotherapy
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regimens in recurrent GBM. 5 Thirty-six patients
received bevacizumab, 36 received nitrosureas, 12
received temozolomide, and 33 received other
agents. It was noted that TTFs alone were comparably
effective and had lower toxicity profile and better
quality of life. This landmark study led to the FDA
approval of NovoTTF-100A™ System (Novocure, Ltd.,
Haifa, Israel) as stand alone treatment for recurrent
GBMs. Subsequently several post-hoc analyses of this
trial were conducted which showed subsets of
patients in whom TTFs alone resulted in improved OS
compared to second line chemotherapy (11.8 vs 9.2
months). 6 Rulesh et al, in 2012, published their series
of twenty patients with recurrent GBM who had been
treated with TTFs between 2004 and 2007. 7 They
reported four long term survivors who were still alive
at the time of publication. According to the authors,
this was the first clinical study to have looked at the
use of TTFs in recurrent GBM. However, the data
reported on the original patients was quite limited
and molecular characteristics of tumours in the
survivors were not elucidated, hence not many
conclusions can be drawn from it. Two trials are
currently for recurrent GBM refractory to
bevacizumab, and bevacizumab naive recurrent
GBM. 8,9

interesting to note that tumour cells may develop
some resistance to TTFs.

Conclusion
The introduction and popularization of tumour
treating fields is a remarkable development in GBM
treatment since the introduction of the Stupp protocol
in 2005. It offers an entirely new area for research and
possible options for treatment. So far, studies have
shown promising results with this treatment modality,
with the added benefit of minimal toxicity and
improved quality of life compared to standard
chemoradiation options.
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